Predicting PD-1 Inhibitor Response via Stem Cell Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PD-L1 axis inhibitors, such as anti-PD-L1 antibodies, have limited efficacy as only a minor subset of patients benefit from the therapy, with unknown mechanisms for predicting response, necessitating a method to identify patients likely to benefit from PD-L1 axis inhibitor treatment.
Innovation Solution
An in vitro method to determine the abundance of stem cell maintenance-related genes in tumor tissue samples, specifically detecting the expression levels of ASPM, CNOT3, LRP5, and PBX1, to predict patient response to PD-L1 axis inhibitors, using techniques like qPCR, RNA-seq, and immunohistochemistry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-L1 axis inhibitors are used to treat cancer patients, then tumor growth can be suppressed in some patients, but only a minor subset of patients benefit from the therapy
Solution Approach 1:
The patent applies preliminary action by assessing stem cell maintenance gene expression levels in tumor tissue samples before initiating PD-L1 axis inhibitor therapy. This baseline molecular characterization allows identification of patients likely to benefit from treatment, enabling selective administration to improve overall therapy efficacy and reduce waste on non-responders.
2Reliability
If PD-L1 axis inhibitors are administered to cancer patients, then clinical outcome can be improved in responsive patients, but the mechanism for predicting response is currently unknown
Solution Approach 1:
The patent introduces stem cell maintenance gene expression as an intermediary biomarker that mediates between tumor biology and therapy response. Specific genes (such as ASPM, CNOT3, LRP5, PBX1) serve as measurable proxies for stem cell-like phenotype, which in turn predicts responsiveness to PD-L1 axis inhibitors, thus bridging the knowledge gap in response prediction mechanisms.
3Measurement precision
If stem cell maintenance gene expression is measured in tumor tissue, then patient response can be predicted, but the method requires complex molecular analysis
Solution Approach 1:
The patent applies segmentation by focusing measurement on a specific subset of genes (stem cell maintenance genes) rather than performing comprehensive genomic profiling. This targeted approach measures only the relevant molecular features (ASPM, CNOT3, LRP5, PBX1) that predict response, simplifying the analytical workflow while maintaining high prediction accuracy.
Data Source
AI summary
The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determing the abundance of stem cell maintenance-related genes in a tumor tissue sample. The abundance of stem cell maintenance-related genes characterized by enhanced expressions of ASPM, CNOT3, LRPS and PBX1 predicts clinical response to the PD-L1 blockade treatment.